Mind your "Q"s: QPharma acquires Qforma
Combination expands breadth of commercialization and compliance services
Two New Jersey-based companies, both with expertise in life sciences commercial services, will now be known only as QPharma. Qforma, until now owned by a private investment firm, BelHealth Investment Partners, has developed analytics technology for “understanding and penetration” of professional relationship networks among healthcare providers and their affiliations, as well as a launch planning tool, iLaunch.
For 21 years, QPharma has provided a range of IT-based services, including systems validation, sample distribution management, state and federal transparency reporting and salesforce training. More recently, it has moved into key opinion-leader (KOL) identification, influence mapping and analytics.
“The purchase of Qforma is a natural progression of the incremental growth strategy that has served QPharma well in the past two decades,” said QPharma president and CEO, Patrick Den Boer, in a statement. “The outstanding technology platform and solution base they have built is a perfect complement to QPharma’s suite of business intelligence tools.”
Purchase price was not disclosed. QPharma says that its national headcount will get a 10% bump-up, but didn't release a total employment figure.
Strategizing High-Wire, Multi-Indication Launches
February 14th 2024Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.
